A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

• Status: Terminated
• Trial end date: 2015-12-25
• Target enrollment: 0
• Participant gender: Female

Summary

This study will investigate the individual safety and efficacy of two dual PI3K/mTOR inhibitors in patients with recurrent endometrial cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Gedatolisib

Criteria

Inclusion Criteria:

• Recurrent endometrial carcinoma

• Disease progression following one or two lines of prior treatment with platinum containing chemotherapy

• Tumor tissue available at time of screening for PI3K analysis

• Adequate performance status

• Adequate glucose control, bone marrow, kidney, liver, and heart function

Exclusion Criteria:

• More than 2 prior cytotoxic chemo regimens for endometrial carcinoma

• Prior therapy with an agent known to be a PI3K, and or mTOR and or AKT inhibitor

• Active brain metastases